NCT04518280View on ClinicalTrials.gov

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

September 1, 2023

Study Completion Date

January 1, 2025

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

PD-1 antibody

PD-1 antibody (Toripalimab): 240mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid d1-14 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

RADIATION

Short-course radiotherapy

Shor-course radiotherapy: 25Gy/5Fx

Trial Locations (3)

200032

Shanghai Changhai Hospital, Shanghai

Zhen Zhang, Shanghai

Unknown

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER